about
Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.TT genotype of rs2941484 in the human HNF4G gene is associated with hyperuricemia in Chinese Han men.Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy.CKD.QLD: establishment of a chronic kidney disease [CKD] registry in Queensland, Australia.Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies.Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studiesLower ADD1 gene promoter DNA methylation increases the risk of essential hypertensionPlasma Urate and Risk of a Hospital Stay with AKI: The Atherosclerosis Risk in Communities Study.Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.Nonapnea Sleep Disorders in Patients Younger than 65 Years Are Significantly Associated with CKD: A Nationwide Population-Based Study.Asymptomatic hyperuricemia following renal transplantation.Uric acid is associated with microalbuminuria and decreased glomerular filtration rate in the general population during 7 and 13 years of follow-up: The Tromsø Study.Targeting Uric Acid and the Inhibition of Progression to End-Stage Renal Disease--A Propensity Score Analysis.Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosisEGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.Protective effect of rosiglitazone, quercetin, and their combination on fructose-induced metabolic syndrome in rats.Serum uric acid and AKI: is it time?Is there a link between hyperuricemia, morning blood pressure surge, and non-dipping blood pressure pattern in metabolic syndrome patients?Elevated Serum Uric Acid Is Associated with Greater Bone Mineral Density and Skeletal Muscle Mass in Middle-Aged and Older Adults.Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome.A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease.The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.Hyperuricemia and chronic kidney disease: an enigma yet to be solved.Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3.Impact of hyperuricaemia on the chronic kidney disease-associated risk factors in a community-based population.Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study.RETRACTED: Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms.Recent advances on uric acid transporters.Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.Oxidative stress induces renal failure: A review of possible molecular pathways.Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.
P2860
Q30876545-FD37A2B1-13D9-4F90-9CEB-257C97F03B7DQ33634704-1F33E0ED-AFEE-4DDF-910F-7BB5083BAAC1Q33688869-8A626FEC-2C12-44A6-BEBD-0299D89BEEB5Q33772238-434C0532-6BC7-41E3-B4B3-2CE4E5718577Q33776530-58724D67-C11E-4371-BCF0-A716EE82FFF4Q33779697-A98281D9-50CF-4EAF-8A61-4352AC0A0FD8Q33800813-74DCD62D-BED5-4B12-A58A-000A81BBF5C2Q34042891-732F92EF-493E-4339-A65F-A6B182D1436FQ34730465-B6EBC65C-70E7-4069-B606-A7955D746567Q35576084-32E49F5B-3DA9-40B0-A51D-02B62EB1A856Q35605560-1B255701-5E53-4D72-AD87-6F1F31F085FFQ35806577-207ADF4A-AFA6-43E6-8E6B-B8390CB56B08Q35819404-0C5703F4-0980-4F3B-9CDE-27E0C39E7607Q35864682-46CA1F7D-8076-4CA4-A2D5-A96D3CCE3D53Q35877440-86399810-DE89-4C7A-857A-A30CE9544F29Q36100197-86651601-3BBF-450E-8087-970953CD9E35Q36223297-B67C5A2C-C7AB-4EEC-9476-9250F92BB1BCQ36398157-A8E27448-BD9C-4E22-B2F6-08B7FB0088F9Q36482934-B89246D5-A104-4367-BF5D-8EB9E8E96BFEQ36824979-E08C80B0-C36A-45FB-87EC-5531A5AF9136Q36868814-600F6C18-5AF2-417A-BC90-FCCE9AEB86B8Q37447055-7598F7BD-C5DB-4671-8474-372C5E961A21Q37674565-4AC8B028-DE4E-4BB7-B4E3-7133E37C2BCAQ37681556-F819F8EB-5664-497A-921B-888B6F39BCABQ37734160-8E5CBFDD-7A2A-40CF-9D3D-E88CF80A28AAQ38138322-3186A352-1627-48F8-84FE-B198CBACB6A7Q38238942-3A51415F-2366-46B3-A79D-74A332EFC620Q38810539-8003A67B-740A-49E0-AB80-D25053C9ED7CQ38970541-194BC876-19F4-4F6C-BDFD-5AED6EE6A2DCQ39039079-CE03A420-667B-4C0C-A653-7D63E242EE54Q41026359-F461F0A9-EF11-49DF-B470-D06363D5E0C6Q41343048-AFB15290-8060-4EA1-8651-F44159511EFDQ41479624-1A92C1DF-FB51-4CFD-94F2-61F0C02C74F0Q41583378-4800B4FD-45DE-4B14-889A-9A34EB471022Q42042957-D1BCFC54-923E-4E72-804F-CB48DF132E7FQ42563749-556DC0D3-BD86-49E7-B180-F8C7D87AFBEEQ47131336-2F109815-93F6-4E3A-AF0A-D5F338EF3ACAQ47169238-5E0EAADB-4BA5-412B-A7A7-42E9A9E83D3AQ47642456-FED4F991-1CD5-4EA8-A9CE-2A59AA46838BQ47733127-7485E2B2-3725-4384-8329-F791F528A226
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Uric acid as a target of therapy in CKD.
@ast
Uric acid as a target of therapy in CKD.
@en
type
label
Uric acid as a target of therapy in CKD.
@ast
Uric acid as a target of therapy in CKD.
@en
prefLabel
Uric acid as a target of therapy in CKD.
@ast
Uric acid as a target of therapy in CKD.
@en
P2093
P2860
P1476
Uric acid as a target of therapy in CKD.
@en
P2093
Diana I Jalal
Giovanni Targher
Michel Chonchol
P2860
P304
P356
10.1053/J.AJKD.2012.07.021
P577
2012-10-09T00:00:00Z